Symbol
| CD47
| contributors: mct/npt - updated : 13-06-2012
|
HGNC name
| CD47 molecule
|
HGNC id
| 1682
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
constitutively upregulated in myeloid leukemias | tumoral
|  
|  
| --over
|  
|
in acute myeloid leukemia contributes to pathogenesis by inhibiting phagocytosis of these cells through the interaction of CD47 with SIRPA, and is associated with decreased overall survival | tumoral
|  
|  
| --over
|  
|
in acute lymphoblastic leukemia | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| important biomarker in breast cancer, and functions as a prognostic factor for disease-free survival | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | hemopathy | | |
development of an anti-CD47 antibody therapy for treatment of acute lymphoblastic leukemia | cancer | | | |
compelling target for therapeutic strategies that reduce its functional interaction with macrophage SIRPA and thus render these cancers susceptible to innate and adaptive immune system clearance | neurology | acquired | | |
may be a potential neurovascular target for stroke and brain injury | cancer | | | |
blockade of its function leads to tumor cell phagocytosis and elimination. CD47 is therefore a validated target for cancer therapies |
| | |
| thymocyte numbers are reduced approximately twofold in CD47-/- mice |